Eurazeo (RFp)

Eurazeo SE is a private equity and venture capital firm specializing in growth capital, series C, acquisitions, leveraged buyouts, and buy-ins of a private company, and investments in upper mid-market, mid-market and listed public companies, small- and mid-cap healthcare companies, equity in the small-mid and mid-large buyout segments. The firm seeks to invest in medium-sized or large companies, SMEs, high growth companies, and real estate management and investment activities. It does not have any restrictions regarding the sectors in which it invests but prefers to invest in smart cities, services, leisure and mobility, real estate, fintech, investment activities, distribution, industry, luxury, consumer goods, business services, consumer and retail brands, and health sectors. The firm seeks to invest in consumer brands with a focus on beauty, digital health, life science, tech, financial services, personal care, household care, juvenile products, apparel, wellness, accessories, home, jewellery, leisure, health, fitness, beverage, and food companies based in United States and Europe. It typically invests in companies with a differentiated concept and global growth potential. The firm identifies companies upstream, carefully selecting them primarily from sectors driven by digital transformation and focusing on changes in lifestyle and consumption (mobility, online buying, collaboration models, etc. The firm invests in large properties in need of restructuring; residential, commercial, and office development projects; and companies with real estate assets in Western Europe. It primarily invests in New York, United States, Paris, France, Italy, North America, China and other European countries. It seeks to invest between €50 million ($54.35 million) to €250 million ($271.77 million) in small mid buyout business. It seeks to invest between €25 million ($27.18 million) and€100 million ($108.71 million) in growth business. It seeks to invest between €10 million ($10.82 million) and €40 million ($43.82 million) in the fields of healthcare research. It seeks to invests between equity investment between €1 million ($1.17 million) and €559.01 million ($600 million) with sales value between €10 million ($11.28 million) and €200 million ($211.73 million) and enterprise value is between €20 million ($21.22 million) and €5000 million ($5366.62 million) in between mid-large buyout enterprise value is between €500 million ($541.94 million) and €1.5 billion ($1625.82 million) and in small mid buyout enterprise value is between €100 million ($108.39 million) and €500 million ($541.94 million). It prefers to makes debt investment between €5 million ($5.37 million) and €100 million ($107.33 million) in between leveraged loans funding between €10 million ($10.73 million) and €50 million ($53.67 million) per transaction. It limits each investment to less than 10 percent to 15 percent of its net asset value. The firm prefers to make investments with transactions above $100 million as co-investments. It prefers to acquire majority stakes in its portfolio companies along with minority stakes. The firm may invest in public companies either taking the public company to private, and then doing a leveraged buyout or in the form of private investment in public equity (PIPE). The firm invests for a period of five to seven years. It exits its investment by sale to a manufacturer, sale to a financial investor, or through an IPO. Eurazeo SE was founded in 1969 and is based in Paris, France with additional offices in North America, Asia, Europe and South America.